Nurix Therapeutics, Inc.
NRIX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001549595
In the last 90 days, Nurix Therapeutics, Inc. insiders filed 0 open-market purchases and 10 sales; 211 institutions reported holding it in 13F filings for Q2 2026, worth $2.84B in total; ARK Invest is the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Nurix Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 10 filings
- 3 insiders, $1.40M in total
- Insiders trading
- 3
- Net value
- −$1.40M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Nurix Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Ring Christine | Chief Legal Officer | 9,110 | Sep 2, 2026 | 18 |
| Hansen Gwenn | Chief Scientific Officer | 117,227 | Sep 1, 2026 | 11 |
| van Houte Hans | Chief Financial Officer | 40,166 | Aug 4, 2026 | 8 |
| Gregory Julia P | Director | 10,750 | May 15, 2026 | 1 |
| Reinsdorf Judith A | Director | – | May 15, 2026 | 1 |
| Silva Paul M | Director | – | May 15, 2026 | 1 |
| Baynes Roy D. | Director | – | May 15, 2026 | 1 |
| Kapur Anil | Director | – | May 15, 2026 | 1 |
| Lacey David L. | Director | – | May 15, 2026 | 1 |
| Dansey Roger D | Director | – | May 15, 2026 | 2 |
| Saltzman Edward C | Director | – | May 15, 2026 | 1 |
| Sands Arthur T | President, CEO | – | Feb 10, 2026 | 1 |
| Kunkel Lori Anne | Director | 0 | May 19, 2025 | 0 |
| Wolff Stefani | EVP and COO | 6,113 | May 2, 2023 | 0 |
| Siegall Clay B | Director | – | May 6, 2022 | 0 |
| Beaurang Pierre | Chief Business Officer | 4,330 | Aug 11, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 2, 2022 (view filing) | Aug 1 | 1 day | Hansen GwennChief Scientific Officer | SSale | −1.19K | $15.67 | −$18.6K | −5.8%19.2K after | |
| May 3, 2022 (view filing) | May 2 | 1 day | Hansen GwennChief Scientific Officer | SSale | −1.10K | $11.75 | −$12.9K | −6.0%17.2K after | |
| May 3, 2022 (view filing) | May 2 | 1 day | Wolff StefaniEVP and COO | SSale | −330 | $11.75 | −$3.88K | −34.3%632 after | |
| May 3, 2022 (view filing) | May 2 | 1 day | van Houte HansChief Financial Officer | SSale | −697 | $11.75 | −$8.19K | −24.2%2.19K after | |
| May 3, 2022 (view filing) | May 2 | 1 day | Ring ChristineGeneral Counsel | SSale | −660 | $11.75 | −$7.75K | −16.2%3.40K after | |
| Jan 11, 2022 (view filing) | Jan 10 | 1 day | Ring ChristineGeneral Counsel | SSale | −1.20K | $27.14 | −$32.6K | −48.3%1.29K after | |
| Jan 4, 2022 (view filing) | Jan 3 | 1 day | Hansen GwennChief Scientific Officer | SSale | −1.83K | $28.96 | −$52.9K | −11.4%14.2K after | |
| Dec 13, 2021 (view filing) | Dec 10 | 3 days | Ring ChristineGeneral Counsel | SSale | −1.20K | $29.04 | −$34.8K | −48.3%1.29K after | |
| Dec 2, 2021 (view filing) | Dec 1 | 1 day | Hansen GwennChief Scientific Officer | SSale | −400 | $29.13 | −$11.7K | −2.7%14.2K after | |
| Nov 12, 2021 (view filing) | Nov 10 | 2 days | Ring ChristineGeneral Counsel | SSale | −1.20K | $32.38 | −$38.9K | −48.3%1.29K after | |
| Nov 2, 2021 (view filing) | Nov 1 | 1 day | Hansen GwennChief Scientific Officer | SSale | −400 | $33.24 | −$13.3K | −2.7%14.2K after | |
| Oct 28, 2021 (view filing) | Oct 27 | 1 day | Ring ChristineGeneral Counsel | SSale | −800 | $35.25 | −$28.2K | −38.4%1.29K after | |
| Oct 28, 2021 (view filing) | Oct 27 | 1 day | Hansen GwennChief Scientific Officer | SSale | −400 | $35.00 | −$14.0K | −2.7%14.2K after | |
| Oct 12, 2021 (view filing) | Oct 11 | 1 day | Ring ChristineGeneral Counsel | SSale | −1.20K | $27.36 | −$32.8K | −48.3%1.29K after | |
| Oct 4, 2021 (view filing) | Oct 1 | 3 days | Hansen GwennChief Scientific Officer | SSale | −400 | $29.92 | −$12.0K | −2.7%14.2K after | |
| Sep 13, 2021 (view filing) | Sep 10 | 3 days | Ring ChristineGeneral Counsel | SSale | −2.00K | $35.93 | −$71.9K | −60.9%1.29K after | 3 lots |
| Sep 8, 2021 (view filing) | Sep 7 | 1 day | Ring ChristineGeneral Counsel | SSale | −3.20K | $35.25 | −$112.8K | −71.3%1.29K after | |
| Sep 8, 2021 (view filing) | Sep 7 | 1 day | Hansen GwennChief Scientific Officer | SSale | −1.60K | $35.00 | −$56.0K | −10.1%14.2K after | |
| Sep 2, 2021 (view filing) | Sep 1 | 1 day | Hansen GwennChief Scientific Officer | SSale | −400 | $32.34 | −$12.9K | −2.7%14.2K after | |
| Aug 11, 2021 (view filing) | Aug 10 | 1 day | Ring ChristineGeneral Counsel | SSale | −1.20K | $29.87 | −$35.8K | −59.9%805 after | |
| Aug 11, 2021 (view filing) | Aug 10 | 1 day | Beaurang PierreChief Business Officer | SSale | −7.50K | $29.86 | −$223.9K | −63.4%4.33K after | 2 lots |
| Aug 3, 2021 (view filing) | Aug 2 | 1 day | Hansen GwennChief Scientific Officer | SSale | −400 | $31.21 | −$12.5K | −2.8%13.8K after | |
| Jul 21, 2021 (view filing) | Jul 20 | 1 day | Ring ChristineGeneral Counsel | SSale | −1.20K | $27.00 | −$32.4K | −59.9%805 after | |
| Jul 12, 2021 (view filing) | Jul 12 | Same day | Beaurang PierreChief Business Officer | SSale | −7.50K | $23.93 | −$179.4K | −63.4%4.33K after | 2 lots |
| Jul 2, 2021 (view filing) | Jul 1 | 1 day | Hansen GwennChief Scientific Officer | SSale | −400 | $26.76 | −$10.7K | −2.8%13.8K after |